EYWA PHARMA INC Levetiracetam Recall: Critical Foreign Tablet Contamination Exposes Supply Chain Vulnerabilities
EYWA PHARMA INC initiated a Class II recall (D-0109-2021) for 5,451 bottles of Levetiracetam Tablets, USP 500 mg, due to 1000 mg tablets found in 500 mg bottles. This critical quality control failure, originating from Indian manufacturer VKT Pharma, underscores significant supply chain risks for procurement and regulatory teams. The recall, initiated November 2020, was terminated October 2024, indicating resolution but demanding continued vigilance.
FDA Class II Recall: Critical Quality Control Lapses in Levetiracetam Packaging
The U.S. Food and Drug Administration (FDA) announced a Class II recall, identified as D-0109-2021, for EYWA PHARMA INC's Levetiracetam Tablets, USP 500 mg, distributed nationwide across the USA. This action, voluntarily initiated by EYWA PHARMA INC on November 10, 2020, stemmed from a critical quality control failure: the discovery of a 1000 mg Levetiracetam Tablet within a bottle explicitly labeled for 500 mg tablets. Specifically, 5,451 bottles from Lot #: LEV5019021A, with an expiration date of October 2021 and NDC 71930-063-52, were affected. For procurement directors and regulatory affairs heads, this incident highlights a severe breakdown in manufacturing and packaging controls at the source, VKT Pharma Private Limited in Srikakulam, India. Such a mix-up carries substantial patient safety risks, from potential overdose to therapeutic failure, directly exposing pharmaceutical companies to significant liability, reputational damage, and costly market withdrawals. It mandates an immediate review of incoming quality control protocols for all Levetiracetam shipments and a reassessment of supplier audit frequencies to prevent similar occurrences.
Immediate Commercial Impact and Supply Chain Disruption for Levetiracetam
The Class II classification of this recall, voluntarily initiated by EYWA PHARMA INC, signifies that the product could cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. The nationwide distribution of 5,451 bottles of the affected Lot #: LEV5019021A means that a significant volume of Levetiracetam Tablets, USP 500 mg, was impacted across the United States. For supply chain VPs, this event translates into immediate operational challenges, including the logistical complexities and financial burden of retrieving affected product from the market. Beyond the direct costs of the recall, there are potential implications for market availability, especially for a critical antiepileptic drug like Levetiracetam. Business development executives must consider the potential for short-term supply gaps and the need to reassure downstream partners and healthcare providers about supply continuity. This incident underscores the necessity for robust inventory management systems and clear contingency plans to mitigate the commercial fallout from such quality deviations.
Manufacturing Origin and Supplier Oversight: VKT Pharma Private Limited's Role
The Levetiracetam Tablets, USP 500 mg, subject to this recall, were manufactured by VKT Pharma Private Limited located in Srikakulam, India, and manufactured for EYWA PHARMA INC, based in Princeton, NJ. This clear distinction between the US-based recalling firm and the Indian manufacturing facility is crucial for understanding supply chain risk. For procurement directors, this highlights the inherent complexities and heightened due diligence required when sourcing active pharmaceutical ingredients (APIs) or finished dosage forms from contract manufacturing organizations (CMOs) in different regulatory jurisdictions. The incident points to potential gaps in VKT Pharma Private Limited's manufacturing process controls or EYWA PHARMA INC's oversight mechanisms. Regulatory affairs heads must ensure that quality agreements with international manufacturers are exceptionally stringent, covering all aspects of quality control, packaging, and deviation management. The commercial implication is that reliance on offshore manufacturing, while often cost-effective, necessitates a proportionally greater investment in supplier qualification, regular audits, and robust quality management systems to safeguard product integrity and market access.
Mitigating Supply Chain Vulnerabilities for Critical Molecules like Levetiracetam
While specific alternative suppliers for Levetiracetam are not detailed in our current intelligence, this recall by EYWA PHARMA INC serves as a critical reminder for procurement teams to proactively address single-source reliance, particularly for essential medicines. Levetiracetam, as an antiepileptic drug, is vital for patient care, making supply continuity paramount. Supply chain VPs should prioritize strategies for geographic diversification of manufacturing sites and the qualification of multiple suppliers for critical APIs and finished products. This involves significant upfront investment in supplier audits, establishing robust quality agreements, and conducting thorough due diligence to ensure alternative manufacturers meet stringent FDA and international regulatory standards. The qualification timeline for new suppliers can be extensive, often spanning 12-24 months, emphasizing the need for foresight. Business development executives must factor these lead times into their product launch and market expansion strategies, recognizing that a resilient supply chain, built on diversified and thoroughly vetted partners, is a competitive advantage that mitigates against unforeseen disruptions and regulatory actions.
Broader Industry Context: Persistent Quality Control Challenges in Pharma Supply Chains
The EYWA PHARMA INC Levetiracetam recall, driven by foreign tablet contamination, is not an isolated incident but rather indicative of persistent quality control challenges across the global pharmaceutical supply chain. Recent parallel events highlight a broader pattern of regulatory scrutiny and product recalls stemming from manufacturing deficiencies. For instance, Advanced Nutriceuticals faced a recall due to sterility assurance lapses, while Real Clean Distribuciones SA de CV's hand sanitizer recall was linked to methanol contamination, exposing critical risks for US importers. Similarly, AVKARE Inc.'s Dutasteride recall highlighted impurity failures, and Teva's Metformin recall underscored ongoing NDMA contamination issues and CGMP risks. Assurance Infusion also experienced a Class II recall for LIPO B due to sterility breaches. For senior decision-makers, these events collectively underscore that regulatory bodies like the FDA are maintaining heightened vigilance over manufacturing quality and supply chain integrity. This environment demands that procurement directors and regulatory affairs heads implement comprehensive risk assessment frameworks that extend beyond immediate supplier relationships to encompass the entire manufacturing ecosystem, ensuring that all partners adhere to the highest standards of Good Manufacturing Practices (GMP) and quality assurance.
Recall Termination and Ongoing Due Diligence for Supply Chain Resilience
The FDA officially terminated the recall D-0109-2021 for EYWA PHARMA INC's Levetiracetam Tablets on October 16, 2024. This termination signifies that the recalling firm, EYWA PHARMA INC, has completed all necessary actions to remove or correct the product in question to the FDA's satisfaction. While the immediate regulatory action for this specific lot is closed, the underlying manufacturing quality system at VKT Pharma Private Limited and the oversight mechanisms employed by EYWA PHARMA INC remain critical areas for ongoing evaluation. For procurement directors, this means that while the immediate crisis has passed, continued vigilance is paramount. It is essential to verify that the root cause of the foreign tablet contamination has been thoroughly investigated, and effective Corrective and Preventive Actions (CAPAs) have been implemented and validated by VKT Pharma Private Limited. Regulatory affairs heads should maintain open communication with their manufacturing partners to ensure sustained compliance and proactively address any potential future deviations. The commercial implication is that long-term supplier relationships must be built on a foundation of continuous quality improvement and transparent communication, ensuring that past issues do not recur and jeopardize future supply or market access.